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Strategic importance and value of embryonic
phenotyping
The International Mouse Phenotyping Consortium (IMPC;
www.mousephenotype.org) aims to create 20,000 knockout (KO)
mouse strains over the next 10 years, with viable strains undergoing
comprehensive phenotyping as adult mice in order to identify the
consequences of gene disruption. It is estimated that at least 30%
of all KO strains will die during embryonic or perinatal periods
and will not, therefore, pass through the adult phenotyping pipeline.
However, systematic identification of such homozygous lethal KO
lines presents the scientific community with a unique opportunity
to study thousands of lethal phenotypes, unlocking a treasure trove
of information relevant to gene function during embryonic growth,
differentiation and organogenesis. This potential has been
recognised by the mouse genetics community, as evidenced by
previous IMPC workshops (Toronto, April 2010; Barcelona,
February 2011), focus groups and user surveys in which embryonic
development was considered an important stage that should be
included in the IMPC pipeline (Brown and Moore, 2012).
Identifying and characterising embryonic lethal mutant
phenotypes is particularly important for understanding the roles
of genes for which little to nothing is known. Embryonic lethal
screens in model organisms, ranging in complexity from
invertebrates to mammalian models, have to date proved extremely
successful for the identification of genes and pathways that control
developmental programmes. Recent case studies in the mouse
include gene trapping (Cox et al., 2010) and chemical mutagenesis
(Boles et al., 2009) screens covering proportions of the X
chromosome and chromosome 11, respectively. These screens have
demonstrated the power of forward genetic approaches for
revealing functions of poorly annotated genes. For example, in the
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Identifying genes that are important for embryo development is a crucial first step towards understanding their many
functions in driving the ordered growth, differentiation and organogenesis of embryos. It can also shed light on the origins
of developmental disease and congenital abnormalities. Current international efforts to examine gene function in the
mouse provide a unique opportunity to pinpoint genes that are involved in embryogenesis, owing to the emergence of
embryonic lethal knockout mutants. Through internationally coordinated efforts, the International Knockout Mouse
Consortium (IKMC) has generated a public resource of mouse knockout strains and, in April 2012, the International Mouse
Phenotyping Consortium (IMPC), supported by the EU InfraCoMP programme, convened a workshop to discuss developing
a phenotyping pipeline for the investigation of embryonic lethal knockout lines. This workshop brought together over
100 scientists, from 13 countries, who are working in the academic and commercial research sectors, including experts
and opinion leaders in the fields of embryology, animal imaging, data capture, quality control and annotation, high-
throughput mouse production, phenotyping, and reporter gene analysis. This article summarises the outcome of the
workshop, including (1) the vital scientific importance of phenotyping embryonic lethal mouse strains for basic and
translational research; (2) a common framework to harmonise international efforts within this context; (3) the types of
phenotyping that are likely to be most appropriate for systematic use, with a focus on 3D embryo imaging; (4) the importance
of centralising data in a standardised form to facilitate data mining; and (5) the development of online tools to allow open
access to and dissemination of the phenotyping data.
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X chromosome gene trap screen, 58 genes were analysed, 19 were
embryonic lethal, of which 17 displayed novel phenotypes and nine
were associated with human genetic disease.
Characterising embryonic lethal phenotypes is also extremely
important from a clinical perspective. Developmental anomalies
and birth defects collectively affect 1/40 births in Europe (Dolk et
al., 2010), equivalent to 360,000 children each year, with a huge
social, health and economic impact on society. The generation and
characterisation of mouse models for these conditions will help to
shed light on the underlying mechanisms responsible for such
defects and the genes responsible. For example, mouse models have
played a central role in our understanding of ciliopathies, for which
the discovery of the relationship between cell signalling and cilia
function has increased our understanding of a diverse spectrum
of human diseases (Norris and Grimes, 2012). Analysis of mouse
embryonic lethal mutations has also resulted in the identification
of new drug targets and intervention strategies. For instance,
studying the neural tube defect in the lethal Grhl3 mouse mutant
model (Greene and Copp, 1997) led to novel inositol and folic acid
combination therapies for the prevention of spina bifida, which 
are currently being evaluated in clinical trials as part of the 
PONTI study at University College London (UCL)
(www.pontistudy.ich.ucl.ac.uk). Moreover, there have been
substantial clinical impacts from fundamental observations of
gene-dosage-sensitive embryonic lethality in delta-like ligand 4
(Dll4; encoding a Notch ligand) and vascular endothelial growth
factor (Vegf) mouse mutants; the products of these genes are
important factors driving angiogenesis, making them major
therapeutic targets in cancer treatment (Garber, 2007).
A large proportion of homozygous lethal mutations also have
clinical phenotypes as viable heterozygotes. Such alleles are likely to
be widely represented in human disease because of their
haploinsufficient or dominant phenotypic effects. Studying
embryonic lethal phenotypes can therefore also provide insight into
the underlying mechanisms relevant to adult disease. This underlines
the substantial and complementary value of combining phenotyping
of heterozygous mutants for clinical phenotypes with detailed
analysis of homozygous lethal phenotypes, to enable a deeper
understanding of gene function and pathways. An important example
is congenital heart disease, which can be caused by semidominant
mutations in the NKX2.5 gene. These mutations were originally
identified and characterised as fly and mouse embryonic lethal
mutations that cause early cardiac failure (Schott et al., 1998).
The IMPC plans to carry out a broad phenotype analysis of
heterozygous adults for those mutants that are non-viable
homozygotes. Such embryonic lethals are predicted to make up at
least 30% of all mutant lines created, based on preliminary data
and bibliometric analysis from The Jackson Laboratory (JAX)
Mouse Genome Informatics (MGI) database (Table 1).
Understanding embryonic lethal phenotypes will be directly
relevant when interpreting adult mouse heterozygous phenotypes
that are detected in the IMPC pipeline. The combination of
embryonic data correlated with adult phenotypes will substantially
strengthen the case for an essential role played by the target gene
in adult disease and is likely to encourage further validation studies
in mice and humans.
In summary, phenotyping mutants that die as embryos is justified
because it will provide missing functional information and clinical
significance to nearly one third of all International Knockout Mouse
Consortium (IKMC) and IMPC mouse lines. Furthermore, the
proposal is extremely timely and cost-effective because it leverages
existing investments that have been made in KO mice that are being
created and bred as part of the IMPC.
This article summarises the conclusions of the April 2012 IMPC
workshop held in London, UK, to discuss the most effective ways
to undertake the phenotyping of mutant mouse embryos and to
incorporate this into the overall programme of the IMPC. This
includes identifying the embryonic stages that are most fruitful for
analysis, determining the types of phenotyping feasible for the scale
of the work and addressing the importance of disseminating
phenotype data to the wider scientific community.
Key embryonic stages of lethality reveal functional
significance
The general findings from several large-scale mutagenesis
programmes, including the most recent data from the EUMODIC
Table 1. Breakdown of mouse embryonic and perinatal lethality  
Number of mice 
with defect 
Total number of 
mice analysed 
Proportion with 
defect (%) 
Homozygous mutant phenotype 
Total embryonic and perinatal lethals reported in the MGI database 1853 6110 30 
Categories of embryonic/perinatal lethals 
‘Early’: before 9 days of gestation 302 1853 16 
‘Mid-gestation’: between 9-14 days of gestation 637 1853 34 
‘Late’: after 14 days of gestation 914 1853 49 
Anatomical defects observed 
Cardiac 491 1853 26 
Genito-urinary, palate, thymus, lungs, trachea, gut, liver, diaphragm, spleen, pancreas 562 1853 30 
Brain, spine, eye, ear 525 1853 28 
Skeletal and limbs 273 1853 15 
Any structural defect 1094 1853 59 
Approximate stages of embryonic development are given in the conventional manner as estimated days of gestation, with E0.5 designated as the first embryonic day (by detection 
of vaginal plug). 
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project (paper in preparation), is that ~30-40% of homozygous KO
mutant strains are embryonic or perinatal lethal. Although lethal
mutations can affect all embryonic stages of development (up to
19 days of gestation), it is useful to consider three broad
developmental stage categories based on the type of cellular and
organ physiology that is affected (Copp, 1995): (1) early lethals with
defects in pre- and peri-implantation processes in embryonic or
extraembryonic tissues; (2) mid-gestational lethals, which die
during organogenesis owing to, for example, a failure in embryonic
cardiovascular function, as well as defects in important placental
functions; and (3) late lethals, which die in the fetal or immediate
perinatal period owing to failures in the transition to adult
functioning organ systems. Bibliometric data collected from the
MGI database is consistent with these observations (Table 1).
Structural defects in the anatomy of many organ systems can be
detected during each stage of embryogenesis. Two important
points are revealed by this observation. First, structural changes
are common indicators of embryonic dysfunction, because 60% of
lethals exhibit abnormal anatomy, which can be detected by simple
observation. Below, we propose to establish a robust and high-
throughput platform to screen intact mammalian embryos for such
defects using imaging techniques. Second, it is impossible to
consider one stage as optimal for the discovery of newly identified
phenotypes. Each stage could reveal important discoveries into
developmental processes, and the stage of particular interest for
follow-up investigations will depend on the interest of the
researcher. This observation is supported by a survey of the UK
Medical Research Council (MRC) Mouse Network Developmental
Anomalies Consortium, a network of 20 UK labs working with
mouse models to study a range of human congenital diseases and
birth defects. Table 2 is a matrix that summarises the great
variability in preferred embryonic stage and current methods for
analysis, broken down by clinically relevant organ systems.
Imaging modalities for embryonic analysis
A major focus of the London workshop was to consider the different
imaging platforms that could be used in a high-throughput screen
of embryonic phenotypes. It was agreed that primary anatomical
information can and should be recorded via visual examination of
mutant embryos by expert annotators. However, the ability to
record three-dimensional (3D) images of mutants at different
appropriate stages, in digital form, adds considerable value to the
primary information. It allows quantitation of morphological
changes, and, as computational tools become broadly available, it
will allow automated scoring of some defects by comparison with
wild-type standards. The data will be stored digitally, ensuring ease
of export and analysis by other labs.
Many imaging platforms were discussed during the workshop
(Table 3), some that have been ‘workhorses’ during previous
screens [e.g. magnetic resonance imaging (MRI) (Schneider et al.,
2004; Dazai et al., 2011)] and others that are on the cutting edge
of dynamic embryo imaging [e.g. optical coherence tomography
(OCT) (Larina et al., 2011)]. When discussing the relative merits
of a platform, an obvious driver is that whole-embryo coverage is
obtained to ensure all organ systems are observed. Further
considerations include spatial resolution and the importance of
sufficient contrast to detect significant changes in morphology. For
instance, in the case of MRI and micro X-ray computed tomography
(μCT) imaging, the development of contrast reagents has helped
enormously. A notable example is the use of inorganic iodine and
phosphotungstic acid as contrast reagents in μCT imaging in order
to increase the detection of soft tissues in mouse embryos
(Metscher, 2009). Another important concern is speed of
acquisition of images, both to detect dynamic changes and for rapid
collection of image volumes [e.g. by applying ultrasound or optical
coherence tomography (OCT) (Zhou et al., 2004; Larina et al.,
2011)]. Additional considerations include operational workflow
issues, complexity and time required for tissue preparation, image
collection and throughput, capital and operational costs, and the
robustness and scalability of the platform. This last point is crucial,
particularly for newly emerging platforms that have yet to be
validated for high-throughput embryo imaging. Consider the
example of a relatively new platform called high resolution episcopic
microscopy (HREM), which combines the ‘gold standard’ sensitivity
and resolution of histopathology with 3D reconstruction (Weninger
et al., 2006). In this platform, embryos are embedded in plastic and
serially sectioned, before each block face is imaged using a high-
resolution digital camera. Serial sections can be assembled digitally,
providing volume data that can be used to reconstruct embryos in
3D with the same cellular resolution as routinely obtained via
Table 2. Results from the UK MRC Mouse Network Developmental Anomalies Consortium survey on the preferred methods of analysis at 
different developmental stages for various organ systems 
Organ system  
Mouse embryonic stage of development (days of gestation) 
<E10.5 E11.5 E12.5 E13.5 E14.5 E15.5 E16.5 E17.5 >E18.5 
Ciliopathies Imaging   lacZ             
CNS     lacZ           Imaging 
Cranio-facial      Histology   Imaging, skeletal 
prep 
Eye     lacZ           Histology 
Gonads, genitalia       Imaging       Imaging   
Heart and vascular     lacZ     Imaging       
Kidney         Histology     Histology   
Neural tube   Morphology             Imaging 
Palate     lacZ       Imaging     
Pituitary, hypothalamus     lacZ         Imaging   
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
dmm.biologists.org574
SPECIAL ARTICLE Mouse embryo phenotyping recommendations
histological sections (1 μm). Not only does HREM have a higher
resolution than most platforms, it can be applied following a non-
destructive imaging method such as MRI or μCT.
The workshop did not come to a consensus on a common
imaging platform. Instead, it was concluded that multiple platforms
exist that can meet the requirements for whole-embryo coverage,
sensitivity, specificity and resolution. In order to optimise the use
of currently available infrastructure and to encourage further
development of high-throughput embryo imaging technologies
(Zhang et al., 2010), it is recommended that appropriate standards
of throughput, sensitivity and specificity be adopted by the
consortium as a whole, as opposed to relying on a particular
imaging platform.
It was clear from many case studies that imaging platform
technology is evolving rapidly, both through incremental platform-
specific method development as well as step change improvements
through novel optics and instrumentation. It is highly
recommended, therefore, that IMPC production centres establish
close collaborations with expert imaging research laboratories or
align themselves with experienced imaging cores. Collaborating
imaging labs would contribute expert advice and technical know-
how of platform technology, image processing and analysis tools.
If an IMPC production centre does not have the necessary imaging
platform technology or expertise, operational aspects of an
embryonic lethal screening pipeline could be outsourced to one or
several of these external imaging labs, as is the case for both of the
KO lethal projects described later in this article.
A tiered and triaged screening strategy for
phenotyping embryonic lethals
The operational workflow for embryonic lethal analysis should be
organised into primary, secondary and tertiary ‘tiers’. A tiered
approach is favoured because it enables flexibility in experimental
design and an affordable breeding strategy. Production centres
would first determine the approximate stage of lethality and score
a minimum set of embryonic phenotypes in a primary tier screen.
These lines would be triaged further for more detailed 3D imaging
or extended analysis at different embryonic stages, depending on
the local research interests and strategic focus as well as availability
of the appropriate imaging platform.
Primary tier: determine approximate stage of lethality
and evaluate a minimum set of phenotypes
The identification of embryonic lethal mutants begins with careful
evaluation of genotype ratios during breeding to generate cohorts
of mice for adult phenotyping. Lethality is defined as the lack of
homozygous animals upon genotyping (usually near wean); at least
28 animals must be genotyped prior to calling a strain lethal at 95%
confidence. Those that display less than 50% of the expected
number of homozygotes (or 12.5% total) will be defined as ‘sub-
Table 3. Summary of imaging platforms for embryonic lethal phenotyping that were discussed at the London workshop 
Parameter Histology Ultrasound 
Magnetic 
resonance 
High-resolution 
episcopic 
microscopy 
(HREM) 
X-ray computed 
tomography 
(μCT) 
Optical 
projection 
tomography 
(OPT) 
Optical 
coherence 
tomography 
(OCT) 
Contrast Uses stain Poor Excellent 
Excellent: 
fluorescent dyes 
Excellent: iodine 
counterstain 
Excellent: 
fluorescent dyes Excellent 
Resolution (μm) 1 50  25  1  2  5  4-8 
Sensitivity and 
specificity ‘Gold standard’ 
Poor for structural 
malformations, 
good for detecting 
flow 
90% and 100%, 
respectively ‘Gold Standard’ Untested Untested 
Very good for 
detecting both 
structural and flow 
defects at specific 
stages 
Time window Any >E12 >E12 Any Untested <E13 
<E10.5 for whole 
embryo; E3.5-
E18.5 for certain 
tissues in utero 
3D reconstruction 
Tedious because 
registration is 
difficult 
No Yes Yes Yes Yes 
Yes, 4D 
reconstruction is 
also possible 
Throughput Poor High 
Medium: 16-32 
embryos in 
12 hours 
Low: one embryo 
at E14.5 in 18-20 
hours and at E9.5 
in 4-5 hours 
Medium: seven 
embryos in
6 hours 
High High 
Portability 
Commercial 
instrument 
available 
Commercial 
instrument 
available 
Commercial 
instrument 
available 
No commercial 
instrument yet; 
customised 
instrument 
Commercial 
instrument 
available 
Commercial 
instrument 
available; 
customized 
instrument 
option 
Best examples 
from custom 
systems; 
commercial 
instruments for 
some uses 
Automated image 
analysis No No Yes Yes Yes Yes Yes 
Experience in 
large-scale screens No Yes Yes 
Medium (several 
hundred to date) 
Medium (several 
hundred to date) Yes No 
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
Disease Models & Mechanisms 575
SPECIAL ARTICLEMouse embryo phenotyping recommendations
viable’, although this is a qualitative assessment and not statistically
significant. Both fully lethal and sub-viable strains can be flagged
for embryonic lethal phenotyping, depending on the centres
involved. The essential first step is to establish the approximate age
of embryonic death for the expected 30% of lethal IMPC lines. A
mid-gestational stage of embryonic day 12.5 (E12.5) was
recommended as a single initial reference time point, which
provides the most information for subsequent analysis at different
time points and can be efficiently combined with lacZ analysis.
Based upon the findings at the E12.5 stage, the screen should then
be triaged to either E9.5 (if there were no live homozygotes at E12.5)
or E18.5 (if there was the expected number of homozygotes at
E12.5). It is important to consider perinatal lethals, because they
are expected to represent a large fraction (~15%) of lethals. In
addition, they are likely to represent excellent models for birth
defects in humans, as evidenced by those linked to human neural
tube defects (Harris and Juriloff, 2010). Triaging to stage E15.5
would follow if lethality was determined to occur in the E12.5-E18.5
window. A minimum of 28 embryos per time point is recommended
to provide 95% confidence for a ‘lethal’ call if no live homozygous
embryos are identified at a particular stage (as above) and, assuming
full penetrance of the phenotype, this number will also be sufficient
to achieve at least seven homozygous mutants for phenotypic
analysis. This strategy to start at E12.5 is in line with the minimum
requirement from the National Institutes of Health (NIH) KO
Mouse Project (KOMP; http://grants.nih.gov/grants/guide/rfa-
files/RFA-RM-10-013.html), thus maximising efficiency for the
consortium. All phenotypes will be captured using standard
annotation and vocabularies [Mouse Phenotype Ontology (MP)
terms; see below].
Secondary tier: detect anatomical anomalies using 3D
imaging
Follow-on phenotyping of appropriate developmental stages
beyond E12.5, dependent on the observations of the first-pass
screen at E12.5, should include acquisition of morphological
information using 3D imaging and anatomical analysis. This tier
will not only provide insights into embryonic phenotypes beyond
that readily observable by gross inspection, but will also archive
high-resolution data sets for additional analysis by experts around
the world. Robust imaging platforms discussed in Table 3, including
MRI, μCT, optical projection tomography (OPT) and HREM, are
recommended to be employed depending on resource availability
and exact stage of analysis. For visual examination, a minimum of
two mutants (depending on the platform) should be imaged from
each stage. Control data from wild-type mice should be collected
from a range of stages to establish standard values to compare with
mutant data. Image data would be initially examined manually,
using commercially available visualisation software.
Computer-assisted analysis
To go beyond descriptive phenotyping and to ameliorate the need
for major efforts and costs of expert annotators, the further
development of quantitative and statistically based computer
analyses is required. These methods bring multiple 3D images into
a common atlas space using methods of spatial deformation. These
‘registered’ images have several valuable attributes. First, at the
simplest level they allow for visual comparison among individual
images within a coherent space. Second, the extracted deformation
fields can be used to identify displacements and volume changes
between embryos. Such quantitative measures can be used to
evaluate statistically abnormal morphology in mutant embryos
compared with controls, taking account of the random variation
within strains. Such statistical evaluation requires group sizes of
about seven mutants and seven controls. Third, manual
segmentation of the atlas enables organ identification and
measurement in each individual 3D image, enabling quantitative
organ measurement. Finally, computer-aided analysis is capable of
detecting subtle but statistically significant changes in gross
morphology that cannot be recognised by visual inspection or by
histological morphometry. These computer-aided analysis methods
are well established for the mouse brain (Dorr et al., 2008; Cleary
et al., 2011) and have shown promise in the initial analysis of
embryos (Zamyadi et al., 2010). A segmented atlas (Fig. 1) from a
set of 35 embryo CT images has recently been published (Wong
et al., 2012), and will be an invaluable resource for computer-
assisted phenotyping of embryonic lethals.
In order to facilitate secondary-tier phenotyping, standard
operating procedures will need to be developed and shared between
production centres in the same manner that the IMPC has created
common protocols for the adult phenotyping pipeline. Given that
the long-term goal of the IMPC is to expand the overall mouse
phenotyping capacity of the international community, an important
component of this tier will be the provision of training, and
transferring expertise, in acquiring and analysing the data obtained
from advanced imaging modalities. This will serve to extend the
capabilities of the consortium overall, while also providing a robust
mechanism for process standardisation. Finally, as with the primary
tier, it is essential that all phenotype calls use the standardised
vocabulary of the MP terms to assure integration and to support
robust search functionality in databases.
Embryonic gene expression profiles
An optional approach for further characterisation is to profile gene
expression via RNA sequencing (RNA-seq) of embryonic tissues,
in order to determine global perturbations caused by the mutation.
Recent work by the Wellcome Trust Sanger Institute’s Zebrafish
Mutation Project has demonstrated the sensitivity and scalability
of RNA-seq for high-throughput mutant analysis by combining
exon-resequencing with morphological phenotype analysis
(www.sanger.ac.uk/Projects/D_rerio/zmp/). However, it should be
noted that mRNA profiling by RNA-seq will not provide cellular
resolution for the targeted gene in the same way that lacZ imaging
does, and so the former should be considered as a subsidiary
approach. As sequencing technologies continue to improve, this
recommendation might be revised.
Investigation of the placenta
Evaluation of the placenta is crucial for accurate descriptions of
embryonic lethal phenotypes to be made, because many embryonic
lethals are the indirect result of defects in trophoblast development,
allantois-chorion fusion or placental function (Rossant and Cross,
2001). Furthermore, conditional deletion of the IKMC KO alleles
could separate embryonic and placental gene functions (Ouseph
et al., 2012). As a minimum, placentae should be evaluated for gross
morphology, and preferably subjected to midline histological
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
dmm.biologists.org576
SPECIAL ARTICLE Mouse embryo phenotyping recommendations
sectioning to enable assessment of the size and morphology of the
different functional layers of the chorioallantoic placenta. Samples
should be collected or banked for further secondary-tier analysis
either locally, or through centralised providers.
Analysis of live embryos
Primary defects in early embryonic lethal mutants (<E12.5) are
difficult to detect because they are often masked by secondary
disorders. Many mutants that are dead or dying but not fully
resorbed present deficits in cardiovascular function that can result
from primary defects in heart function, blood differentiation or
the vascular system. In these cases, dynamic analysis is needed to
assess the phenotype. Live-embryo imaging using technologies such
as ultrasound and OCT provide the earliest functional tests of heart
function and blood flow analysis, and are a sensitive way to identify
defects in heart function or blood formation. Secondary screens
on live embryos can further define which of these three systems
are affected first, and can also provide a full 3D structural analysis
of embryos without added exogenous contrast agents (Larina et
al., 2011).
Tertiary tier: functional analysis by end users
More detailed tertiary phenotyping would be performed by
individual investigators who have flagged strains of interest within
the primary and secondary phenotyping tiers. The types of follow-
up would typically include detailed immunohistochemistry, laser
capture micro-dissection and the development of cell-based assays.
Further analysis of the underlying tissue defects would require
tissue- and temporal-specific KOs using the IKMC floxed alleles
and appropriate Cre drivers. This would necessitate the
involvement of experienced users. The production centres are
encouraged to develop networks of collaborators who would
benefit from accessing the mutant embryos to facilitate their
research.
lacZ reporter analysis: adding value to phenotyping
Because the alleles used in creating KO mouse strains in the IMPC
also carry a lacZ reporter gene (Skarnes et al., 2011), the majority
of investigators considered that lacZ expression analysis in embryos
would provide essential insight into the cellular, tissue and organ
expression patterns predicted for the targeted gene. Detailing lacZ
expression at E12.5 was recommended by the UK development
consortium (Table 2) and is being adopted as part of the NIH-
funded KOMP phenotyping programme in the IMPC.
Therefore, an important recommendation for a lethal screen is
to incorporate lacZ analysis. This integration has substantial
benefits, including being able to combine embryo production
during cohort breeding when generating homozygous lethals, the
ability to correlate developmental defects with tissue expression
profiling, and the possibility of employing common imaging
platforms to capture both general anatomy and structure as well
as information on reporter gene expression [e.g. OPT (Sharpe et
al., 2002)]. It would also leverage and extend the in situ hybridisation
embryo surveys of gene expression (EurExpress) (Diez-Roux et al.,
2011).
To capitalise on embryo analysis efforts, workshop participants
recommended analysing lacZ expression in E12.5 embryos and in
adults (P50 or older) for each lethal KO strain in order to correlate
possible roles in development with discernible adult lacZ expression
or identified phenotypes. Also, the analysis of both male and female
heterozygous animals was recommended in order to identify
defects in reproductive development and anatomy. Many human
congenital anomalies show sex-dependent differences in
prevalence, encouraging the analysis of both male and female lethal
lines to gain insight into the mechanisms of these poorly understood
sex differences (Lary and Paulozzi, 2001). It was also strongly
recommended that pilot studies employing lacZ staining of
homozygotes are undertaken, because these provide increased
signal (allowing for more sensitive detection) and can also provide
insight into the mutant phenotype (e.g. through detection of
deregulated expression or altered anatomy). Wild-type littermates
(no lacZ) and ubiquitously expressing lacZ-positive control animals
were recommended to be included in the analysis. The exact
methods for tissue fixation and processing vary among different
groups, but include whole-mount staining, frozen sectioning,
paraffin embedding, OPT or combinations of modalities. A list of
40 adult tissues to be annotated was agreed upon and includes
substructures as covered by the mouse anatomy (MA) ontology
vocabulary. An equivalent set of high-level ontological terms for
the embryonic stages will need to be agreed upon as a matter of
priority by the community through further discussions via the
IMPC forum. Each tissue entity will be scored as present, absent,
non-specific, or tissue not available. As a minimum, 2D digital
images, including a scale bar, will be captured and archived for
positive staining tissues. Meta-data, such as the production centre,
staining modality and standard operational procedure used, should
also be captured and linked to the image data.
Exemplar embryonic lethal phenotyping pipelines
Two embryonic lethal screens are already in progress or being
considered, both of which will implement a tiered and triaged
approach. The first screen encompasses the NorCOMM2 (North
American Conditional Mouse Mutagenesis) and KOMP2 projects,
at the University of Toronto’s Center for Phenogenomics (TCP),
which follow the workflow that is summarised in Fig. 2. The TCP
screen identifies homozygous lethal lines by genotyping at 2-3
weeks of age. Lethal lines are initially examined at the mid-
Fig. 1. Three-dimensional visualisation of 48 segmented anatomical
structures in an E15.5 mouse embryo atlas. Each volume is shown in its
native location within the whole mouse embryo volume (semi-transparent).
Note that many of the segmented labels cannot be displayed because they are
embedded within other structures, especially in the brain.
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gestational stage (E12.5) for developmental anomalies, with
heterozygous embryos stained for lacZ reporter activity. Standard
whole-mount imaging is used, and OPT is also being piloted in
combination with lacZ expression analysis to detect developmental
anomalies in homozygous mutant embryos. Those strains that
survive to E12.5 are analysed further at E14.5 or E15.5 using μCT
imaging, whereas those strains that fail to develop normally to E12.5
are followed up at the earlier E9.5 stage using OPT. 3D imaging is
supported by detailed histopathology of both embryonic and
placental tissues.
The second screen is being undertaken by a consortium of UK
developmental biologists and clinician scientists supported by the
Wellcome Trust. This programme, entitled ‘Deciphering the
Mechanisms of Developmental Disorders (DMDD)’, will screen at
least 50 embryonic lethal strains, produced by the Wellcome Trust
Sanger Institute, each year over a 5-year period [see accompanying
Editorial (Mohun et al., 2013). The DMDD screen incorporates a
tiered, triaged strategy in which embryonic and perinatal lethals
are identified 2 weeks after birth, with lethal strains initially
examined at E14.5-E15.5 using a combination of μCT and HREM
imaging platforms. As with the TCP pipeline, embryonic and
placental tissues will both be examined, and those strains that
appear morphologically normal at the initial stage of examination
will be further analysed later (in this case at E18.5 by histopathology
and immunohistochemistry) or earlier (E9.5-E10.5 by HREM).
Although lacZ reporter activity for the targeted gene will not be
assessed in the DMDD screen, embryos will undergo RNA-seq
analysis to determine transcriptome profiles.
Data analysis and dissemination
The logistics of disseminating, analysing and annotating the 3D
data were identified as a major challenge during the workshop. The
first aspect to consider is the need for data coordination to ensure
minimum quality-control standards before data release for expert
user or general public annotation. An excellent case study for
coordinating operational and data quality-control workflows for a
high-throughput multi-site embryo expression analysis has been
demonstrated by the EUREXPRESS project (Diez-Roux et al., 2011).
This project analysed over 18,000 genes and 400 microRNAs by
oligo-based RNA in situ hybridisation on wild-type embryos
(E14.5; cryosections). In keeping with the IMPC ideology, once they
have passed the necessary quality-control measures, all data must
be made freely available pre-publication through the IMPC
database (www.impc.org). In order to deliver on this ambitious goal,
a coordinated effort will be required to make 3D image data
available in an open-source environment.
Another major challenge is that of data interpretation and
annotation. Realistically, it will be impossible for a single IMPC
production centre to provide enough embryological expertise and
capacity to annotate every organ system in hundreds of animals,
across multiple stages and under different imaging platforms. Our
proposal organises embryonic phenotyping into tiers, wherein the
first level of characterisation is within the capacity and expertise
of the various centres. For the second level it is essential, therefore,
to make datasets available in such a way that experts and general
users can access the primary data for their own analysis. This will
require the development and implementation of systems for
handling very large image datasets, and for making them available
to the user community for visualisation and analysis. To facilitate
this, it is essential that centres should adopt common strategies for
data collection, storage, quality control and transfer in order to
create a common interface or portal for the internal and external
community. The visualisation platforms and tools should be
implementable independent of the imaging modality, overcoming
the problem of having multiple imaging data types. Platform-
independent 3D analysis tools are already well established in the
HET x HET 
lacZ (1 litter) 
Genotype 28 embryos (5 litters)  
E12.5 lethal check-point 
>12.5% HOM <12.5% HOM 
E15.5 μCT  
E9.5 OPT 
if >12.5% HOM 
+ Histopathology embryo and placenta 
Count pups (P0 and P14-21) 
Genotype 28 pups @ P14-21 
>0% HOM 
genotyped 
HOM viable HOM sub-viable 
>12.5% 12.5% 
HOM in ADULT 
pipeline 
HET in ADULT 
pipeline 
0% HOM 
genotyped 
No pup death Pup death P0-P21 
HOM in NEONATAL 
LETHAL pipeline 
(7-8 HOM + 
 2 WT) 
Fig. 2. The TCP lethal screen. Outline of the
screening procedure of the University of Toronto’s
Center for Phenogenomics (TCP) to identify and
phenotype recessive embryonic lethal mutants
produced from the NORCOMM2 and KOMP2
projects. Heterozygous KO mice (HET) are crossed,
the offspring counted on the day of birth (P0),
followed by genotyping of 28 surviving pups 2-3
weeks later (P14-P21) to establish the proportion
of wild-type (WT), heterozygous mutant and
homozygous mutant (HOM) animals produced. If
no homozygote mutants are detected despite the
absence of any neonatal pup death, the KO is
considered embryonic lethal and ~five litters (28
embryos) are checked for survival of homozygous
embryos to the 12th day of gestation (E12.5).
Embryos are imaged by μCT on the 15th day of
gestation (E15.5) or OPT on the 9th day (E9.5),
depending on whether more or less than 50% of
the expected mendelian ratio of homozygotes is
detected, respectively.
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biomedical imaging community and can be adopted for initial review
by qualified embryologists as a crucial component of embryonic
lethal analysis. However, mapping and annotating this information
will need to be coordinated. A framework already exists for doing
so, based on the Edinburgh Mouse Atlas Project (Baldock et al.,
1999) (http://www.emouseatlas.org). This portal allows the detailed
3D analysis of mouse anatomy and allows mapping of information
(e.g. gene expression data from EUREXPRESS) onto anatomical
structures in the developing mouse embryo. This takes advantage
of sophisticated 3D computer models of mouse anatomy and
histology across different developmental stages. The challenge will
be to extend this kind of mapping to include imaging datasets from
the range of platforms considered here (e.g. HREM, OPT, μCT).
Ultimately, an automated system for identifying and annotating
a range of embryonic phenotypes will be developed. Great progress
has already been made in enabling the automated analysis of 3D
data sets in order to assist experts in the identification of
phenotypes. Furthermore, discussions on automated interpretation
based on composite atlases of embryo anatomy have been very
positive. A precedent for automated calling of adult brain
phenotypes using the atlas approach (Cleary et al., 2011) is one
that should be considered as the community moves forward with
a large-scale embryo phenotype programme.
The final major challenge will be to capture a phenotype using
standard annotation and vocabularies. This is essential if data are
to be analysed in a meaningful way to enable reliable, cross-
comparable phenotype calls between centres, and proper indexing
and searching in databases without an extensive need for data
curation. Annotations made by multiple end users and experts will
need to follow searchable phenotype annotations based on the MP
terms (Eppig et al., 2012). One outcome of the meeting was the
agreement that not all MP terms exist for embryos, and the gaps
need to be filled as a matter of priority. These will be posted on
the IMPC website forum. Furthermore, a standard, minimum set
of MP terms should be used for all lethal mutants at the various
stages examined. This set of assembled terms captures phenotypes
that can be assessed by gross morphological evaluation by trained
non-experts, thereby maximising the number of centres that will
be able to contribute to the data set. This would not preclude deeper
analysis of a given mutant by a centre, which would continue to
use MP terms to describe the phenotype, but would provide a
minimum foundation of analysis that the community can expect
from all strains produced.
Costs and resources
The costs for undertaking embryo phenotyping along the lines
recommended will, of course, depend on individual mouse
production centre costs and the precise phenotyping programme
adopted. Nevertheless, to estimate the scale of likely costs, we have
reviewed high-throughput operations at a typical production centre
participating in the IMPC and KOMP2 projects. The total cost to
create and phenotype a single KO line, beginning from targeted
embryonic stem cells, is estimated to be approximately $47,000.
Of this total, the component for actually generating embryos and
carrying out 3D animal imaging and histological analysis following
the efficient triaged approach advocated here, represents only 40%
of the total cost (Fig. 3). Additional high-value analysis, such as
molecular phenotyping by expression profiling (RNA-seq), and
expert annotation of data with publication via a public portal have
also been estimated and represent a further 25% of the total cost
(Fig. 3). Centralising such activities offers further savings because
it would be much more expensive if undertaken by many individual
research groups.
Importantly, the costs associated with KO strain production (36%
of total costs) are already borne by production centres as part of
the IMPC. Combining embryo phenotyping with the IMPC pipeline
therefore is extremely cost-efficient, and we estimate a cost saving
of $25.5 million for the first phase of the international phenotyping
effort in which 5000 KO lines are predicted to generate 1500
embryonic or perinatal lethals. Given the huge potential for driving
embryogenesis research forwards, the marginal extra cost of
embryo phenotyping is, we believe, worth the additional investment
at this early stage of the programme.
Conclusions
The systematic generation of mouse gene KO lines currently in
progress provides a unique opportunity for both developmental
biologists and clinicians. For the former it provides the chance to
determine, in a comprehensive manner, the functional significance
of genes that are essential for embryo development and which
account for approximately one third of the entire genome. For the
latter, it offers the prospect of identifying the genetic components
that underlie developmental disease, in addition to providing
animal models for the investigation of disease aetiologies. The scale
of this task, like that of phenotyping adult mouse KO lines, requires
a coordinated and international effort, but the rewards will be
considerable. This endeavour will provide novel insights into the
underlying developmental processes of organogenesis and embryo
morphogenesis, including information on gene function and
pleiotropy; it will help us to interpret adult KO phenotypes, leading
to better models of human disease to inspire therapeutically
relevant innovation.
Importantly, a coordinated effort to phenotype embryonic lethals
will build upon existing international efforts that have been
established through the work of the IKMC and IMPC. This has
already generated the infrastructural capacity and capability of
generating thousands of KO strains and can therefore deliver
embryos from embryonic lethal lines at relatively minimal
additional effort and cost.
KO mouse production
Molecular profiling
Expert annotation
Embryo production and imaging
Fig. 3. Predicted costs associated with embryo phenotyping. Estimated
breakdown of the costs associated with phenotyping a single KO strain, based
on existing phenotyping programmes and proposals for phenotyping mouse
lines from the IMPC and KOMP2 projects.
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Through their discussions, participants at the IMPC/InfraCoMP
workshop agreed on a common strategy to undertake phenotyping
of embryonic lethal lines, based on a flexible, tiered approach where
an initial screen to determine the approximate stage of death and
reporter gene expression analysis is followed by detailed embryo,
extra-embryonic and perinatal phenotyping. The triaged scheme
allows specific research programmes to focus on the embryonic
stages and follow-on studies that are of strategic scientific importance.
The core of phenotyping will be based on identification of
morphological abnormalities through the use of modern imaging
modalities that are capable of combining whole-embryo coverage
with adequate sensitivity, specificity and resolution. Qualitative and
quantitative analysis of 3D image data will provide the most
reliable way to phenotype embryo malformations.
Coordinated and innovative IT efforts will be necessary to
underpin such an ambitious programme, to ensure open access,
data harmonisation between platforms and the adoption of agreed
phenotyping methods using internationally defined mouse anatomy
and phenotype ontologies.
Finally, the workshop highlighted the urgency of establishing
embryo phenotyping efforts. KO mouse strains from the IMPC are
now becoming available for lethal screening, and national efforts
need to be coordinated as soon as possible, in order to take
advantage of the limited time window during which such a
programme is economically feasible.
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